Peak Bio, Inc. Common Stock
PKBO
PKBO was delisted on the 9th of January, 2023.
9 hedge funds and large institutions have $2.53M invested in Peak Bio, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 40 closing their positions.
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
50.2% less ownership
Funds ownership: 58.7% → 8.5% (-50%)
79% less funds holding
Funds holding: 43 → 9 (-34)
85% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 40
94% less capital invested
Capital invested by funds: $42.7M → $2.53M (-$40.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$3.46M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$355K |
| 3 |
Charles Schwab
San Francisco,
California
|
+$268K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$99.9K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$21.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$7.24M |
| 2 |
WRBC
W.R. Berkley Corp
Greenwich,
Connecticut
|
-$3.7M |
| 3 |
SCM
Saba Capital Management
New York
|
-$3.68M |
| 4 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$2.63M |
| 5 |
DKCM
Davidson Kempner Capital Management
New York
|
-$2.25M |
PKBO Hedge Fund Activity: Q4 2022 in Review
9 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Peak Bio, Inc. Common Stock (PKBO) for Q4 2022, worth a combined $2.53M — down 94% from $42.7M a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of PKBO and 6 opened new positions — a net loss of 34 holders — while 2 trimmed existing stakes and 1 added.
The largest buyer was Palo Alto Investors, opening a new position worth an estimated $3.46M. The largest seller was Deerfield Management, exiting entirely with an estimated $7.24M sold.
- 9 institutional investors held Peak Bio, Inc. Common Stock (PKBO) as of Q4 2022, down from 43 in Q3 2022.
- Funds reported $2.53M of Peak Bio, Inc. Common Stock stock for Q4 2022, down 94% quarter-over-quarter.
- 6 funds opened new Peak Bio, Inc. Common Stock positions in Q4 2022 and 40 closed out, a net change of -34 holders.
- The largest Peak Bio, Inc. Common Stock buyer in Q4 2022 was Palo Alto Investors, an estimated $3.46M added.
- The largest Peak Bio, Inc. Common Stock seller in Q4 2022 was Deerfield Management, an estimated $7.24M sold.
Based on aggregated 13F filings for Q4 2022.